iBio Inc. Annual report pursuant to Section 13 and 15(d)

Share-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2019

The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):

The following table summarizes all stock option activity during the years ended June 30, 2019 and 2018:


				Weighted-
		Weighted-		average
		average		Remaining	Aggregate
	Stock	Exercise		Contractual	Intrinsic Value
	Options	Price		Term (in years)	(in thousands)
Outstanding as of July 1, 2017	1,354,833	$	12.08	5.9	$	138
Granted	21,000	$	3.12
Forfeited/expired	(11,250)	$	4.00
Outstanding as of June 30, 2018	1,364,583	$	12.01	4.9	$	—
Granted	400,000	$	0.90
Issued under Option Exchange	874,310	$	0.93
Forfeited/expired/exchanged	(1,292,374)	$	12.08
Outstanding as of June 30, 2019	1,346,519	$	1.45	6.1	$	—
As of June 30, 2019 vested and expected to vest	1,324,467	$	1.46	6.1	$	—

Exercisable as of June 30, 2019	70,998	$	10.94	3.6	$	—

The following table summarizes information about options outstanding and exercisable at June 30, 2019:


	Options Outstanding and Exercisable
		Weighted-	Weighted-
		Average	Average
	Number	Remaining Life	Exercise		Number
	Outstanding	In Years	Price		Exercisable
Exercise prices:
$0.93 - $2.03	1,274,435	6.2	$	0.92	166
$2.53 - $4.40	12,750	5.1		3.91	11,498
$5.80 - $8.70	33,334	4.5		6.82	33,334
$9.30 - $26.90	22,000	1.8		17.63	22,000
$26.90 - $28.90	4,000	2.0		28.90	4,000
	1,346,519	6.1	$	1.45	70,998

The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions: